跳转至内容
Merck
CN

K0600000

酮康唑

European Pharmacopoeia (EP) Reference Standard

别名:

(±)--1-乙酰基-4-(4-[(2-[2,4-二氯苯基]-2-[1H-咪唑-1-基甲基]-1,3-二氧戊环-4-基)-甲氧基]苯基)哌嗪

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C26H28Cl2N4O4
化学文摘社编号:
分子量:
531.43
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

酮康唑, European Pharmacopoeia (EP) Reference Standard

InChI

1S/C26H28Cl2N4O4/c1-19(33)31-10-12-32(13-11-31)21-3-5-22(6-4-21)34-15-23-16-35-26(36-23,17-30-9-8-29-18-30)24-7-2-20(27)14-25(24)28/h2-9,14,18,23H,10-13,15-17H2,1H3/t23-,26-/m0/s1

SMILES string

CC(=O)N1CCN(CC1)c2ccc(OC[C@H]3CO[C@@](Cn4ccnc4)(O3)c5ccc(Cl)cc5Cl)cc2

InChI key

XMAYWYJOQHXEEK-OZXSUGGESA-N

grade

pharmaceutical primary standard

API family

ketoconazole

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

正在寻找类似产品? 访问 产品对比指南

Application

CYP3A4抑制剂

Biochem/physiol Actions

抗真菌剂

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Other Notes

Sales restrictions may apply.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

signalword

Danger

Hazard Classifications

Acute Tox. 3 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Repr. 1B - STOT RE 2

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

B Halama et al.
Clinical pharmacology and therapeutics, 93(6), 564-571 (2013-03-21)
The objective of the study was to establish an in vivo method for assessing cytochrome P450 3A (CYP3A) activity using therapeutically inert nanogram doses of midazolam. We administered four escalating single doses of oral midazolam (0.0001-3 mg) to 12 healthy participants
Masato Ohbuchi et al.
Antimicrobial agents and chemotherapy, 57(3), 1332-1338 (2013-01-01)
The antifungal efficacy of voriconazole (VRC) differs among host species, with potent efficacy in humans but less in rodents. We investigated the possible involvement of pregnane X receptor (PXR) and constitutive androstane receptor (CAR) in the species-specific efficacy of VRC
Hao Li et al.
The Journal of biological chemistry, 288(19), 13655-13668 (2013-03-26)
Ketoconazole binds to and antagonizes pregnane X receptor (PXR) activation. Yeast high throughput screens of PXR mutants define a unique region for ketoconazole binding. Ketoconazole genetically interacts with specific PXR surface residues. A yeast-based genetic method to discover novel nuclear
Jan Faergemann et al.
Expert opinion on pharmacotherapy, 8(9), 1365-1371 (2007-06-15)
Seborrhoeic dermatitis (SD) is a chronic, inflammatory skin disorder, affecting areas of the head and body where sebaceous glands are most prominent and active. The disorder commonly affects hair-bearing areas of the head, including the scalp. Involvement on the face
K-H Shin et al.
Clinical pharmacology and therapeutics, 94(5), 601-609 (2013-06-21)
This study aimed to evaluate endogenous metabolic markers of hepatic cytochrome P450 (CYP)3A activity in healthy subjects using a metabolomics approach. Twenty-four subjects received the following medication during the following three study periods: 1 mg of i.v. midazolam alone (control

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持